The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Sebastian GiebelDuring the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, When should we consider allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a patient with ALL? And when not?
When should we consider allo-HSCT in a patient with ALL? And when not?
Allo-HSCT is a very effective method of treatment for ALL, however, it is also associated with a significant risk of mortality. In this video, Giebel discusses tailoring treatment paradigms according to Philadelphia chromosome subtypes and high-risk karyotypes. He also touches upon ongoing studies looking at second- or third-generation tyrosine kinase inhibitors and chimeric antigen receptor (CAR) T-cell therapies that could offer new opportunities for patients with ALL in the future.